Researchers investigated the apparent close relationship between IGG4-RD and AAV and whether they arise from shared pathophysiological pathways. A 60-year-old woman was referred for fever and kidney ...

Serum sickness is a rare but potentially severe complication of rituximab therapy. A patient with newly diagnosed progressive transformation of germinal centers (PTGC) associated with immunoglobulin ...

Genes such as NKG7 and ASCL2 were found to be key drivers of CLL and could inform drug sensitivity profiles. A distinct natural killer (NK) cell subset, termed CLL_NK, is a precursor to effector NK ...

Emerging treatments, like gene and mRNA therapies, offer hope, pending further investigation. The ongoing development of new drugs for Fabry disease is expected to lead to a greater variety of ...

To improve outcomes, neonates with significant comorbidities such as sepsis and perinatal asphyxia on a background of FNAIT should be closely monitored. The prevalence of fetal and neonatal alloimmune ...

Remote epilepsy was strongly linked to poorer neurological outcomes, but timing of diagnosis did not affect long-term prognosis. Perinatal intracranial hemorrhage (pICH), including cases secondary to ...

Extremely low baseline neutrophil count was a strong predictor of early death, underscoring the need for early risk stratification. Treatment with porcine antihuman T-lymphocyte globulin (ATG) and ...

AI’s capacity to analyze and classify large volumes of data can be leveraged to enhance both diagnosis and management in Fabry disease. Artificial intelligence (AI)-based tools could improve the ...

Spontaneous recanalization following thrombotic occlusion without lipid-rich plaque is one of the representative etiologies of coronary artery disease in patients with myeloproliferative neoplasms ...

Over 36% of patients with polycythemia vera, 21.4% of those with primary MF, and 18.8% of those with essential thrombocythemia experienced thrombotic events. Thrombotic events, especially ischemic ...

Patients completing induction and prolonged MTR had a median overall survival of 143 months and a relapse-free survival of 122 months. A prolonged regimen of methotrexate, temozolomide, and rituximab ...

In the case of Fabry disease, renal lysosomal inclusions were used as a surrogate biomarker that contributed to the approval of agalsidase beta. The role of biomarkers in diagnosis, severity ...